Patent Docket P0645P4D2C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Lisa J. Garrard et al. Serial No.: 09/717,641 Filed: November 21, 2000 For: ENRICHMENT METHOD FOR VARIANT PROTEINS WITH ALTERED BINDING PROPERTIES	Group Art Unit: 1636 Examiner: D. Lambertson **CERTIFICATE OF HAND DELIVERY** I hereby certify that this correspondence is being hand delivered to the to: Examiner D. Lambertson, Group Art Unit 1636, USPTO, Washington, D.C. 20231 on April 4, 2003 Reggie Mitchell

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

[] **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

[x] **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

[] **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) **and** a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

[] **37 CFR §1.97(e)**Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

[] **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.

[x] The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of $180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

Those patent(s) or publication(s) which are marked with an asterisk (*) in the attached PTO-1449 form are not supplied because they were previously cited by or submitted to the Office in a prior application Serial No. 08/922,345, filed September 3, 1997 and relied upon in this application for an earlier filing date under 35 USC §120.

A concise explanation of relevance of the items listed on PTO-1449 is:

[x] not given

[] given for each listed item

[] given for only non-English language listed item(s) [Required]

[] in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: April 3, 2003

By: _____

Paul Naik, Ph.D.
Reg. No. 49,075
Telephone No. (650) 225-5530

FORM PTO-1449 U.S. Dept. of Commerce
Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant	
Garrard et al.	
Filing Date	**Group**
21 Nov 2000	1646

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	67	3,853,832		Li			10.12.74
	68	3,853,833		Li			10.12.74
	69	4,446,235	01.05.84	Seeburg			22.03.82
	70	4,655,160		Seeburg			12.05.87
	71	4,670,393	02.06.87	Seeburg			01.03.84
	72	4,699,897	13.10.87	Jones et al.			04.06.83
	73	4,880,910		de Boer et al.			14.11.89
	74	4,888,286	19.12.89	Crea			24.03.87
	75	5,013,653		Haston et al.			07.05.91
	76	5,047,333	10.09.91	Grandi et al.			22.12.88
	77	5,350,836	27.09.94	Kopchick et al.			04.05.92
	78	5,514,548	07.05.96	Krebber et al.			
	79	5,516,637	14.05.96	Huang et al.			
	80	5,580,717	03.12.96	Dower et al.			
	81	5,622,699	22.04.97	Ruoslahti et al.			
	82	5,627,024	06.05.97	Maruyama et al.			
	83	5,658,727	19.08.97	Barbas et al.			
	84	5,702,892	30.12.97	Mulligan-Kehoe			
	85	5,712,089	27.01.98	Borrebaeck et al.			
	86	5,733,743	31.03.98	Johnson et al.			
	87	5,747,334	05.05.98	Kay et al.			31.01.94
	88	5,750,373	12.05.98	Garrard et al.			
	89	5,759,817	02.06.98	Barbas			
	90	5,770,356	23.06.98	Light, II et al.			
	91	5,770,434	23.06.98	Huse			
	92	5,780,279	14.07.98	Matthews et al.			
	93	5,811,093	22.09.98	Merril, C.R. et al.			12.04.96
	94	5,955,341	21.09.99	Kang et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	95	0 089 666 A3		EP				
	96	844,306	27.05.98	EPO				
	97	WO 88/07084	22.09.88	PCT				
	98	WO 88/07578	06.10.88	PCT				
	99	WO 90/05185	17.05.90	PCT				

Examiner | Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 | U.S. Dept. of Commerce, Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant	
Garrard et al.	
Filing Date	**Group**
21 Nov 2000	1646

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	100	WO 90/08823		PCT				
	101	WO 92/09690	11.06.92	PCT				
	102	WO 92/21029		PCT				
	103	WO 93/00109	07.01.93	PCT				
	104	WO 95/34648	21.12.95	PCT				
	105	WO 95/34683	21.12.95	PCT				
	106	WO 96/22393	25.07.96	PCT				
	107	WO 97/09446	13.03.97	PCT				
	108	WO 97/35196	25.09.97	PCT				
	109	WO 97/44491	27.11.97	PCT				
	110	WO 97/46251	11.12.97	PCT				
	111	WO 97/47314	18.12.97	PCT				
	112	WO 98/05344	12.02.98	PCT				
	113	WO 98/15833	16.04.98	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	114	Abdel-Maeguid et al., "Three-dimensional structure of a genetically engineered variant of porcine growth hormone" Proc. National Acad. Sci. (USA) 84:6434-6437 (1987)
	115	Allen et al., "Finding prospective partners in the library: the two-hybrid system and phage display find a match" TIBS 20:511-516 (1995)
	116	Argos, P., "An investigation of protein subunit and domain interfaces" Protein Eng. 2:101-113 (1988)
	117	Aston, R. et al., "Monoclonal antibodies to growth hormone and prolactin" Pharm. Ther. 27:403-424 (1985)
	118	Bajt et al., "Characterization of a Gain of Function Mutation of Integrin αIIbβ3 (Platelet Glycoprotein IIb-IIIa)" The Journal of Biological Chemistry 267(31):22211-22216 (1992)
	119	Barany, G. et al. Solid-Phase Peptide Synthesis 2:3-254 (1979)
	120	Barbas et al., "Assembly of Combinatorial Libraries on Phage Surfaces: The Gene III Site" Proc. Natl. Acad. Sci. USA 88:7978-7982 (1991)
	121	Barbas et al., "Combinational immunoglobulin libraries on the surface of phage (phabs): Rapid selection of antigen-specific Fabs" Methods: A companion to Methods in Enzymology 2:119-124 (1991)
	122	Barbas, "Recent advances in phage display" Current Opinion in Biotechnology 4:526-530 (1993)
	123	Barlow et al., "Continuous and discontinuous protein antigenic determinants" Nature 322:747-748 (1986)
	124	Baumann et al., "A Specific Growth Hormone-Binding Protein in Human Plasma: Initial Characterization" Journal of Clinical Endocrinology and Metabolism 62(1):134-141 (1986)

Examiner | Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant: Garrard et al.	
Filing Date: 21 Nov 2000	Group: 1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	125	Bennett, W.F. et al., "High resolution analysis of functional determinants on human tissue-type plasminogen activator" Journal of Biological Chemistry 266:5191-5201 (1991)
	126	Berendt et al., "The Binding Site on ICAM-1 for Plasmodium falciparum-Infected Erythrocytes Overlaps, but Is Distinct from, the LFA-1-Binding Site" Cell 68:71-81 (1992)
	127	Berlot et al., "Identification of Effector-Activating Residues of Gsα" Cell 68:911-922 (1992)
	128	Bettler et al., "Immunoglobulin E-binding Site in Fcε Receptor (FCεRII/CD23) Identified by Homolog-scanning Mutagenesis" Journal of Biological Chemistry 267:185-191 (1992)
	129	Binder et al., "Site-directed mutations of human growth hormone that selectively modify its lactogenic activity and binding properties" Molecular Endocrinology ((ABSTRACT)) 4(7):1060-1068 (1990)
	130	Boutin et al., "Cloning and Expression of the Rat Prolactin Receptor, a Member of the Growth Hormone/Prolactin Receptor Gene Family" Cell 53:69-77 (1988)
	131	Bradbury and Cattaneo, "The use of phage display in neurobiology" Trends in Neuroscience 18:243-249 (1995)
	132	Breitling et al., "A surface expression vector for antibody screening" Gene 104:147-153 (1991)
	133	Burritt et al., "Filamentous Phage Display of Oligopeptide Libraries" Analytical Biochemistry 238:1-13 (1996)
	134	Burstein et al., "Immunoreactivity and receptor binding of mixed recombinants of human growth hormone and chorionic somatomammotropin" Proc. Natl. Acad. Sci. USA 75(11):5391-5394 (1978)
	135	Camble et al., "Properties of Interferon-alpha2 Analogues Produced from Synthetic Genes" Proceedings of the Ninth American Peptide Symposium, Deber et al. eds. pps. 375-384 (1985)
	136	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" Nucl. Acids Res. 13(12):4431-4443 (June 25, 1986)
	137	Chang et al., "Expression of antibody Fab domains on bacteriophage surfaces potential use for antibody selection" J. of Immunology 147:3610-3614 (1991)
	138	Chawla, R. et al., "Structural variants of human growth hormone: biochemical, genetic and clinical aspects" App. Rev. med. 34:519-547 (1983)
	139	Choo and Klug, "Designing DNA-binding proteins on the surface of filamentous phage" Current Opinion in Biotechnology 6:431-436 (1995)
	140	Chothia, "The Nature of the Accessible and Buried Surfaces in Proteins" Journal Mol. Biol. 105:1-12 (1976)
	141	Clackson and Wells, "In Vitro Selection from Protein and Peptide Libraries." Trends Biotechnol. 12:173-184 (1994)
	142	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" Nature 352:624-628 (1991)
	143	Clayton et al., "Substitution of murine for human CD4 residues identifies amino acids critical for HIV-gp120 binding" Nature 335:363-366 (1988)
	144	Cortese et al., "Epitope discovery using peptide libraries displayed on phage" Tibtech 12:262-267 (1994)

Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant	
Garrard et al.	
Filing Date	**Group**
21 Nov 2000	1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	145	Cortese et al., "Identification of biologically active peptides using random libraries displayed on phage" Current Opinion in Biotechnology 6:73-80 (1995)
	146	Cortese et al., "Selection of biologically active peptides by phage display of random peptide libraries" Current Opinion in Biotechnology 7:616-621 (1996)
	147	Cortess et al., "Epitope discovery using peptide libraries displayed on phage" Tibtech 12:262-267 (1994)
	148	Cunningham et al., "Receptor and Antibody Epitopes in Human Growth Hormone Identified by Homolog-Scanning Mutagenesis" Science 243:1330-1336 (1989)
	149	Cunningham, B. et al., "Rational design of receptor-specific variants of human growth hormone" Proc. natl. Acad. Sci. USA 88:3407-3411 (1991)
	150	Cunningham, et al., "Dimerization of the Extracellular Domain of the Human Growth Hormone Receptor by a Single Hormone Molecule" Science 254:821-825 (1991)
	151	Davies, D. R. et al., "Antibody-Antigen Complexes" Ann. Rev. Biochem. 59:439-473 (1990)
	152	de Haard et al., "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies" Journal of Biological Chemistry 274(26):18218-18230 (June 25, 1999)
	153	de Vos et al., "Human Growth Hormone and Extracellular Domain of its Receptor: Crystal Structure of the Complex" Science 255:306-312 (1992)
	154	DeLano et al., "Convergent solutions to binding at a protein-protein interface" Science 287:1279-1283 (Feb 18, 2000)
	155	Dunn, I.S., "Phage display of proteins" Current Opinion in Biotechnology 7:547-553 (1996)
	156	Edwards, C. et al., "A newly defined property of somatotropin: priming of macrophages for production of superoxide anion" Science 239:769-771 (1988)
	157	Felici, "Selection of antibody ligands from a large library of oligopeptide expressed on a multivalent exposition vector" J. Mol. Biol. 222:301-310 (1991)
	158	Fuh, G. et al., "Rational Design of Potent Antagonists to the human growth hormone receptor" Science 256:1677-1680 (1992)
	159	Ge et al., "Functional domains of Bacillus thuringiensis Insecticidal Crystal Proteins" The Journal of Biological Chemistry 266(27):17954-17958 (1991)
	160	Geysen, "Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid" Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984)
	161	Goeddel et al., "Direct Expression in Escherichia coli of a DNA Sequence Coding for Human Growth Hormone" Nature 281:544-548 (October 18, 1979)
	162	Gray et al., "Periplasmic production of correctly processed human growth hormone in Escherichia coli: natural and bacterial signal sequences are interchangeable" Gene 39:247-254 (1985)
	163	Greenwood et al., "Multiple display of foreign peptides on a filamentous bacteriophage: peptides from plasmodium falciparum circumsporozoite protein as antigens" J. Mol. Biol. pps. 821-827 (1991)
	164	Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" Trends in Biotechnology 15(2):62-70 (Feb 1997)

Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P0645P4D2C3	Serial No. 09/717,641
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		Applicant Garrard et al.	
		Filing Date 21 Nov 2000	Group 1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	165	Houghten et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug recovery" Nature 354:84-86 (1991)
	166	Isaksson, O. et al., "Mode of action of pituitary growth hormone on target cells" Ann. Rev. Physiol. 47:483-499 (1985)
	167	Janin, J. et al., "Surface, subunit interfaces and interior of oligomeric proteins" J. Mol. Biol. 204:155-164 (1988)
	168	Jefferies, D., "Selection of novel ligands from phage display libraries: an alternative approach to drug and vaccine discovery?" Parasitology Today 14(5):202-206 (1998)
	169	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with Those From a Mouse." Nature. 321:522-525 (May 29, 1986)
	170	Kang et al., "Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries" Proc. Natl. Acad. Sci. USA 88:11120-11123 (1991)
	171	Kang et al., "Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces" Proc. Natl. Acad. Sci. USA 88:4363-4366 (1991)
	172	Kobilka et al., "Chimeric α2,β2-Adrenergic receptors: Delineation of Domains Involved in Effector Coupling and Ligand Binding Specificity" Science 240:1310-1316 (1988)
	173	Kostyo et al., "Biological characterization of purified native 20-kDa human growth hormone" Biochimica et Biophysica Acta 925:314-324 (1987)
	174	Krivi et al., "immunohistochemical Expression of Insulin-Like Growth Factor I During Skeletal Muscle Regeneration in Normal. . ." Int'l Symp. On Growth Hormone (Abstract I-18, (Serono Symposia, USA)) (1987)
	175	Lam et al., "A new type of synthetic peptide library for identifying ligand-binding activit[redacted]ature 354:82-84 (1991)
	176	Laskowski et al., "Positive Darwinian Selection in Evolution of Protein Inhibitors of Serine Proteinases" Cold Spring Harbor Symposia on Quantitative Biology 52:545-553 (1987)
	177	Lehninger, "The amino acid building blocks of protein" Biochemistry (Figures 4.2-4.4), 2nd Edition edition, New York, NY:Worth Publishers, Inc. pps. 73-75 (1975)
	178	Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression" Nature 330:537-543 (1987)
	179	Lewis et al., "A Naturally Occurring Structural Variant of Human Growth Hormone" The Journal of Biological Chemistry 253(8):2679-2687 (1978)
	180	Lewis, "Variants of Growth Hormone and Prolactin and their Posttranslational Modifications" Ann. Rev. Physiol. 46:33-42 (1984)
	181	Li et al., "Viable transmembrane region mutants of bacteriophage M13 coat protein prepared by site-directed mutagenesis" Biochm. & Biophys. Res. Comm. 180(2):687-693 (1991)
	182	Li, "Human growth hormone: 1974-1981" Molecular and Cellular Biochemistry 46:31-41 (1982)
	183	Li, C. et al., "Human Pituitary Growth Hormone. XII. The Amino Acid Sequence of the Hormone" J. Am. Chem. Soc. 88:2050-2051 (1966)
	184	Lindqvist and Naderi, "Peptide presentation by bacteriophage P4" FEMS Microbiology Reviews 17:33-39 (1995)

Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant: Garrard et al.	
Filing Date: 21 Nov 2000	Group: 1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	185	Lowman and Wells, "Monovalent Phage Display: A Method for Selecting Variant Proteins from Random Libraries" Methods: Comp. to Methods Enzymol. 3:205-216 (1991)
	186	Lowman, H. et al., "Selection of High-Affinity Variants of Human Growth Hormone by Monovalent Phage Display" Discussion of Mutations at American society of Cell Biology Meeting (1992)
	187	Makowski, L., "Structural constraints on the display of foreign peptides on filamentous bacteriophages" Gene 128:5-11 (1995)
	188	Mandel et al., "Calcium-dependent Bacteriophage DNA Infection" Journal of Molecular Biology (Letter to the Editor) 53:159-162 (1970)
	189	Marklund et al., "Design, construction and function of a multicopy display vector using fusions to the major coat protein of bacteriophage M13" Gene 109:13-19 (1991)
	190	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" J. Mol. Biol. 222:581-597 (1991)
	191	Marseigne et al., "Synthesis and Biological Activity of CCK26-33-Related Analogues Modified in Position 31" Journal of Medicinal Chemistry 31(5):966-970 (1988)
	192	Martal, J. et al., "Involvement of Lysine Residues in the Binding of hGH and bGH to Somatrotropic Receptors" FEBS Letters 180:295-299 (1985)
	193	Matthews et al., "A Survey of Furin Substrate Specificity Using Substrate Phage Display" Protein Science 3:1197-1205 (1994)
	194	Matthews et al., "Substrate phage: selection of protease substrates by monovalent phage display" Science 260:1113-1117 (1993)
	195	McCafferty et al., "Phage-enzymes: expression and affinity chromatography of functional alkaline phosphatase on the surface of bacteriophage" Protein Engineering 4(8):955-961 (1991)
	196	McGregor, "Selection of proteins and peptides from libraries displayed on filamentous bacteriophage" Molecular Biotechnology 6:155-162 (1996)
	197	McLafferty et al., "M13 bacteriophage displaying disulfide-constrained microproteins" Gene 128:29-36 (1993)
	198	Miller, "The structure of interfaces between subunits of dimeric and tetrameric proteins" Protein Eng. 3:77-83 (1989)
	199	Mills et al., "Fragments of Human Growth Hormone Produced by Digestion with Thrombin: Chemistry and Biological Properties" Endocrinology 107(2):391-399 (1980)
	200	Mullinax et al., "Identification of human antibody fragment clones specific for tetanus toxoid in a bacteriophage alpha immunoexpression library" Proc. Natl. Acad. Sci. USA 87:8095-8099 (1990)
	201	Nagashima et al., "Alanine-scanning Mutagenesis of the Epidermal Growth Factor-like Domains of Human Thrombomodulin Identifies Critical Residues for Its Cofactor Activity" Journal of Biological Chemistry 268(4):2888-2892 (1993)
	202	Neri et al., "Engineering recombinant antibodies for immunotherapy" Cell Biophysics 27(1):47-61 (Aug 1995)
	203	Nicoll, C. et al., "Structural features of prolactins and growth hormones that can be related to their biological properties" Endocrine Reviews 7:169-203 (1986)
	204	Nishikawa et al., "Structure and activity of artificial mutant variants of human growth hormone" Protein Engineering ((abstract only)) 3(1):49 (1989)

Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Dept. of Commerce Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant: Garrard et al.	
Filing Date: 21 Nov 2000	Group: 1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	205	O'Boyle et al., "Identification of a novel peptide substrate of HSV-1 protease using substrate phage display" Virology 236:338-347 (1997)
	206	O'Neil and Hoess, "Phage display: protein engineering by directed evolution" Current Opinion in Structural Biology 5:443-449 (1995)
	207	Oliphant et al. Proc. Natl. Acad. Sci. (USA) 86:9094-9098 (1989)
	208	Paladini, A. et al., "Molecular Biology of Growth Hormone" CRC Crit. Rev. Biochem. 15:25-56 (1983)
	209	Rapley, "The Biotechnology and Applications of Antibody Engineering" Molecular Biotechnology 3:139-154 (1995)
	210	Roberts et al., "Protease inhibitor display M13 phage: Selection of high-affinity neutrophil elastase inhibitors" Gene 121:9-15 (1992)
	211	Russell et al., "Recombinant Hormones from Fragments of Human Growth Hormone and Human Placental Lactogen" Journal of Biological Chemistry 256(1):296-300 (1981)
	212	Rutter, W. et al., "Redesigning proteins via genetic engineering" Protein Engineering pps. 257-267 (1987)
	213	Sambrook et al. Molecular Cloning, a Laboratory Manual, Second edition edition, New York:Cold Spring Harbor Laboratory Press pps. 4.1-4.19 (1989)
	214	Sato, K. et al., "Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted with a single D-amino acid" Biochem. and Biophys. Res. Comm. 149:531-537 (1987)
	215	Seeburg, "The Human Growth Hormone Gene Family: Nucleotide Sequences Show Recent Divergence and Predict a New Polypeptide Hormone" DNA 1(3):239-249 (1982)
	216	Shen et al., "Use of site-directed mutagenesis to define the limits of seuquence variation tolerated for processing of the M13 procoat protein by the E. coli leader peptidase" Biochemistry 30:11775-81 (1991)
	217	Shortle, D., "Genetic strategies for analyzing proteins" Protein Engineering pps. 103-108 (1987)
	218	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" Immunological Reviews 130:109-124 (Dec 1992)
	219	Solazzo et al., "Expression of an exogenous peptide epitope genetically engineered in the variable domain of an immunoglobulin: implications for antibody and peptide folding" Protein Engineering 4:215-220 (1990)
	220	Soumillion et al., "Phage display of enzymes and in vitro selection for catalytic activity" Applied Biochemistry and Biotechnology 47:175-190 (1994)
	221	Straley, "The plasmid-encoded outer-membrane proteins of Yersinia pestis" Reviews of Infectious Diseases 10(2):S323-S326 (1988)
	222	Thorner, M. et al., "Growth Hormone" J. Clin. Invest. 82:745-747 (1988)
	223	Tokunaga et al., "Synthesis and expression of a human growth hormone (somatotropin) gene mutated to change cysteine-165 to alanine" European Journal of Biochemistry 153(3):445-449 (March 1, 1985)
	224	Tsunetsugu-Yokota et al., "Expression of an immunogenic region of HIV by a filamentous bacteriophage vector" Gene 99:L261-265 (1991)

Examiner	Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 | U.S. Dept. of Commerce | Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No.	Serial No.
P0645P4D2C3	09/717,641
Applicant	
Garrard et al.	
Filing Date	**Group**
21 Nov 2000	1646

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	225	Venuti, "Chapter 31. The Impact of Biotechnology on Drug Discovery" Annual Reports in Medicinal Chemistry, Vinick, ed. Vol. 25:289-298 (1989)
	226	Wells and de Vos., "Structure and Function of Human Growth Hormone: Implications for the Hematopoietins." Ann. Rev. Biophys. Biomol. Struct. 22:329-351 (1993)
	227	Wells and Lowman, "Rapid Evolution of Peptide and Protein Binding Properties in Vitro" Curr. Opin. Struct. Biol. 2:597-604 (1992)
	228	Wells et al., "Optimizing binding and catalysis by phage display" Protein Eng. 6(suppl):105 (1993)
	229	Wells, "Systematic Mutational Analyses of Protein-Protein Interfaces" Methods in Enzymology 202:390-411 (1991)
	230	Wells, J. et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin" Philos. Trans. Royal Soc. London Ser. A 317:415-423 (1986)
	231	Wertman et al., "Systematic Mutational Analysis of the Yeast ACT1 Gene" Genetics 132:337-350 (1992)
	232	Wharton et al., "Changing the binding specificity of a repressor by redesigning an α-helix" Nature 316:601-605 (1985)
	233	Wharton et al., "Substituting an α-Helix Switches the Sequence-Specific DNA Interactions of a Repressor" Cell 38:361-369 (1984)
	234	Winter and Milstein, "Man-made antibodies" Nature 349(6307):293-299 (Jan 24, 1991)
	235	Winter et al., "Making antibodies by phage display technology" Annual Review of Immunology 12:433-455 (1994)
	236	Zhang et al., "Toward a Simplification of the Protein Folding Problem: A Stabilizing Polyalanine alpha-helix Engineered in T4 Lysozyme" Biochemistry 30:2012-2017 (1991)
	237	Zoller and Smith., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)
	238	Zoller, "New molecular biology methods for protein engineering" Current Opinion in Structural Biology 1:605-610 (1991)

Examiner | Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.